We are developing a proprietary system to isolate and concentrate autologous, homologous-use, regenerative cells found in adipose (fat) tissue. The key value proposition is that these cells can be harvested safely and with minimal discomfort from the patient's own fat tissue in very high quantity so that a therapeutic dose of cells can be provided back to that patient in real-time, without exposing those cells to a cell culture process.
"...dedicated to delivering the highest quality products and services, MacroPore Biosurgery's success is dependent on the quality of its products and services to the customer the hospitals that buy our products, the surgeons who use them and ultimately the patients who benefit from them."
(From MacroPore Biosurgery Corporate Quality Policy)
Currently, we are generating scientific knowledge through internal and sponsored research to support the clinical use of these cells.
Our most advanced research and development program is in the repair of cardiovascular tissues that are damaged after a heart attack. We are also researching applications in bone repair, spinal disc regeneration, and cosmetic and reconstructive surgery.
Our surgical implants, derived from our bioresorbable technology, represent one of the latest advancements in spine and orthopedic medicine. They are manufactured by us and distributed exclusively through Medtronic Sofamor Danek.
To date, we have introduced three bioresorbable product lines for a variety of musculoskeletal applications that are marketed in the United States, Canada, Europe and other countries. We are also developing additional products for use in spinal fusion / reconstruction procedures and other applications.
We believe our regenerative cell and bioresorbable materials platform technologies can potentially be applied across a broad spectrum of medical applications.